YOLFTbeta
Shenzhen Lifotronic Technology Co

Shenzhen Lifotronic Technology Co

688389 · SHG · Healthcare / Medical Devices

11.12CNY-0.27 (-2.37%)

Price History

Full chart

Market Stats

Previous Close11.39
Open11.41
Day Range11.10 – 11.51
52-Week Range9.36 – 14.88
Volume2.64M
Market Cap4.88B
P/E (TTM)33.47
Forward P/E0.00
EPS0.34
Dividend Yield2.48%
Beta0.37
50-Day Avg11.03
200-Day Avg12.18

About

Shenzhen Lifotronic Technology Co., Ltd. researches, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. It offers a comprehensive range of in vitro diagnostic equipment and reagents, including electrochemiluminescence immunoassay analyzers, glycated hemoglobin analyzers, specific protein analyzers, blood analyzers, and related testing reagents, serving hospitals, health check-up centers, and third-party medical testing institutions. The company also provides clinical medical solutions, such as intelligent venous thromboembolism (VTE) prevention systems, wound treatment devices, precision medicine equipment, and pain rehabilitation products for medical institutions; dermatological aesthetics, such as pulsed light therapy devices, shock wave therapy devices, laser therapy machines, and other energy-based medical aesthetic equipment; and therapeutic products comprising respiratory and ICU, and wound care; electromagnetic and pneumatic shockwave products. In addition, the company provides medical and aesthetic, and laser hair removal products, as well as offers E-training services. Further, it offers medical and beauty-related products. Additionally, the company exports its products. Shenzhen Lifotronic Technology Co., Ltd. was founded in 2008 and is headquartered in Shenzhen, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Ming Long Hu
  • Employees1.90K
  • HeadquartersPumen Technology Headquarters Building, No. 8, Shenzhen, China, 518000, China
  • Websitehttps://www.lifotronic.com

Leadership

  • Mr. Ming Long HuDirector & GM · b. 1969
  • Ms. Hong WangCFO & Director · b. 1966
  • Mr. Ying ZengDirector & Deputy GM · b. 1969
  • Ms. Man LuBoard Secretary · b. 1990
  • Mr. Liang QiuDeputy General Manager · b. 1971
  • Mr. Dawei LiDeputy General Manager · b. 1978
  • Jingyi LuoHead of the Accounting Department & Accounting Supervisor

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue174.54M250.83M323.43M422.64M553.82M778.11M983.04M1.15B1.15B1.04B
Growth (%)-+43.71%+28.94%+30.68%+31.04%+40.50%+26.34%+16.55%+0.20%-9.60%
Cost of Revenue69.29M98.41M131.45M168.44M218.85M301.86M412.13M445.10M384.60M381.85M
Gross Profit105.25M152.41M191.98M254.21M334.97M476.25M570.92M700.62M763.44M1.04B
Gross Margin60.30%60.76%59.36%60.15%60.48%61.21%58.08%61.15%66.50%100.00%
Operating Expense115.95M89.17M102.33M141.08M178.44M273.09M314.50M355.57M385.76M855.55M
Operating Income-10.70M63.25M89.65M113.13M156.53M203.16M256.42M345.04M377.68M182.28M
Operating Margin-6.13%25.21%27.72%26.77%28.26%26.11%26.08%30.12%32.90%17.56%
EBITDA20.59M70.21M96.63M121.70M168.39M220.86M282.89M376.89M421.48M217.91M
EBITDA Margin11.80%27.99%29.88%28.80%30.41%28.38%28.78%32.90%36.71%21.00%
Net Income10.38M56.42M81.14M100.56M143.95M190.35M251.48M328.58M345.39M186.09M
Net Income Margin5.95%22.50%25.09%23.79%25.99%24.46%25.58%28.68%30.09%17.93%
R&D39.44M49.97M66.67M77.92M103.33M155.81M170.79M172.68M201.50M228.59M
R&D as % of Total Revenue22.60%19.92%20.61%18.44%18.66%20.02%17.37%15.07%17.55%22.03%
Interest Expense3.92M673.46K212.41K211.75K259.30K571.55K3.25M4.14M7.50M1.34M
Interest Expense % of Total Revenue2.24%0.27%0.07%0.05%0.05%0.07%0.33%0.36%0.65%0.13%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets497.52M710.40M811.93M1.18B1.29B1.47B1.82B2.33B2.89B2.81B
Total Liabilities126.69M123.15M143.53M129.29M145.98M216.50M377.02M533.76M845.13M700.79M
Total Equity370.82M587.25M668.39M1.05B1.14B1.26B1.44B1.80B2.05B2.12B
Cash410.58M497.04M516.74M819.95M844.75M808.71M931.64M1.31B1.72B1.57B
Total Debt-3.32M-600.00K2.10M4.13M132.61M242.50M600.00M-
Net Debt-410.58M-493.72M-516.74M-819.35M-842.66M-804.58M-799.03M-1.07B-1.12B-

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow28.00M35.25M81.14M91.82M136.42M182.07M271.71M303.82M296.47M280.97M
Investing Cash Flow-27.58M-111.43M-58.21M-66.01M-57.45M-130.18M-533.10M-59.97M-58.74M-
Financing Cash Flow205.68M162.66M-3.37M277.68M-50.59M-82.97M52.71M103.12M262.97M-
Capital Expenditure32.20M119.45M73.43M67.33M54.08M121.57M183.62M48.62M62.02M83.44M
Free Cash Flow-4.20M-84.20M7.72M24.49M82.34M60.49M88.09M255.20M234.45M197.53M
Dividends Paid3.84M538.14K171.33K60.00M50.66M75.15M75.15M103.47M125.06M120.83M
FCF to OCF-14.99%-238.85%9.51%26.67%60.36%33.23%32.42%84.00%79.08%70.30%
Dividend Paid to FCF-91.41%-0.64%2.22%244.97%61.53%124.23%85.31%40.54%53.34%61.17%

Earnings

Report DateDec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Mar 20, 2021Apr 17, 2021Aug 6, 2021Oct 22, 2021Apr 15, 2022Aug 19, 2022Oct 28, 2022Apr 27, 2023
EPS Estimate------------
EPS Actual0.080.090.080.060.120.120.070.090.160.080.120.21
Surprise------------
Timing----After-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap4.88B
Enterprise Value3.75B
Trailing P/E33.47
Forward P/E0.00
Price / Sales4.30
Price / Book2.31
EPS0.34
Book Value4.85
Revenue (TTM)1.13B
Gross Profit (TTM)691.42M
EBITDA190.77M
Profit Margin12.51%
Operating Margin14.50%
Return on Equity6.51%
Return on Assets3.65%
Shares Outstanding428.49M
Shares Float203.74M
Beta0.37
Dividend Yield2.48%
Dividend Rate0.28
Payout Ratio82.94%

Dividends

20231×
0.24Jun 8, 2023
20221×
0.18May 23, 2022
20211×
0.18Apr 26, 2021
20201×
0.12May 19, 2020